Zacks: Brokerages Expect Intellia Therapeutics Inc (NTLA) Will Post Quarterly Sales of $11.98 Million
Analysts expect Intellia Therapeutics Inc (NASDAQ:NTLA) to post $11.98 million in sales for the current fiscal quarter, Zacks Investment Research reports. Five analysts have provided estimates for Intellia Therapeutics’ earnings. The highest sales estimate is $18.50 million and the lowest is $7.00 million. Intellia Therapeutics posted sales of $6.67 million during the same quarter last year, which suggests a positive year over year growth rate of 79.6%. The company is expected to issue its next quarterly earnings results on Wednesday, March 13th.
According to Zacks, analysts expect that Intellia Therapeutics will report full-year sales of $34.51 million for the current year, with estimates ranging from $29.55 million to $41.05 million. For the next fiscal year, analysts expect that the firm will report sales of $42.95 million, with estimates ranging from $20.00 million to $95.00 million. Zacks Investment Research’s sales averages are an average based on a survey of research firms that cover Intellia Therapeutics.
Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings results on Wednesday, October 31st. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.05). The company had revenue of $7.41 million during the quarter, compared to analyst estimates of $11.58 million. Intellia Therapeutics had a negative return on equity of 31.70% and a negative net margin of 308.81%. The business’s revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.44) earnings per share.
NASDAQ NTLA traded down $0.56 during midday trading on Thursday, hitting $18.78. The company had a trading volume of 602,129 shares, compared to its average volume of 725,684. Intellia Therapeutics has a fifty-two week low of $16.33 and a fifty-two week high of $35.99.
Several large investors have recently added to or reduced their stakes in the company. Legal & General Group Plc lifted its holdings in shares of Intellia Therapeutics by 75.4% during the 2nd quarter. Legal & General Group Plc now owns 5,427 shares of the company’s stock worth $149,000 after acquiring an additional 2,333 shares during the period. Great West Life Assurance Co. Can lifted its holdings in shares of Intellia Therapeutics by 2.5% during the 2nd quarter. Great West Life Assurance Co. Can now owns 97,031 shares of the company’s stock worth $2,652,000 after acquiring an additional 2,395 shares during the period. TRUE Private Wealth Advisors lifted its holdings in shares of Intellia Therapeutics by 23.5% during the 2nd quarter. TRUE Private Wealth Advisors now owns 13,296 shares of the company’s stock worth $363,000 after acquiring an additional 2,533 shares during the period. Macquarie Group Ltd. bought a new position in shares of Intellia Therapeutics during the 2nd quarter worth about $101,000. Finally, Patriot Financial Group Insurance Agency LLC bought a new position in shares of Intellia Therapeutics during the 3rd quarter worth about $116,000. 66.59% of the stock is owned by institutional investors.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc, a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism programs.
Featured Article: What factors cause inflation to rise?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intellia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.